Table 3.

Clinical trials for BL with SCNSL

StudyRegimenNCNS involvement, %Survival for all patients, %Survival for patients with CNS involvementTRM of all patients, %CNS relapse, %
UKLG LY06118  CODOX-M
IVAC 
52 13 2-y EFS, 65
2-y OS, 73 
1-y, 100 NR 
AMC048119  R-CODOX-M
R-IVAC 
34 12 1-y PFS, 69
2-y OS, 69 
NR 
NCT00001337120  DA-EPOCH-R 19 FFP, 95
OS, 100 
OS, 100 
NCT0109218232  DA-EPOCH-R 113 10 4-y EFS, 84
4-y OS, 87 
4-y EFS, 45 
MDACC single-arm study121  HyperCVAD-R 31  3-y EFS, 80
3-y OS, 89 
3-y OS, 50 NR 
Retrospective study114  HyperCVAD-R 54 28 5-y RFS, 59
5-y OS, 55 
5-y RFS, 26
5-y OS, 23 
15 
StudyRegimenNCNS involvement, %Survival for all patients, %Survival for patients with CNS involvementTRM of all patients, %CNS relapse, %
UKLG LY06118  CODOX-M
IVAC 
52 13 2-y EFS, 65
2-y OS, 73 
1-y, 100 NR 
AMC048119  R-CODOX-M
R-IVAC 
34 12 1-y PFS, 69
2-y OS, 69 
NR 
NCT00001337120  DA-EPOCH-R 19 FFP, 95
OS, 100 
OS, 100 
NCT0109218232  DA-EPOCH-R 113 10 4-y EFS, 84
4-y OS, 87 
4-y EFS, 45 
MDACC single-arm study121  HyperCVAD-R 31  3-y EFS, 80
3-y OS, 89 
3-y OS, 50 NR 
Retrospective study114  HyperCVAD-R 54 28 5-y RFS, 59
5-y OS, 55 
5-y RFS, 26
5-y OS, 23 
15 

DA-EPOCH-R, dose-adjusted infusional EPOCH-R; EFS, event-free survival; FFP, freedom from progression; MDACC, MD Anderson Cancer Center; NR, not reported; RFS, relapse-free survival; TRM, treatment-related mortality.

BL, n = 17 (55%) and B-cell acute lymphoblastic leukemia, n = 14 (45%).

or Create an Account

Close Modal
Close Modal